Articles

Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan

Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine
Department of Oncology and Hematology, Jikei University Kashiwa Hospital
Department of Hematology, International University of Health and Welfare School of Medicine, Narita;Department of Hematology, Chiba University Hospital
Department of Hematology and Oncology, Japanese Red Cross Narita Hospital
Department of Oncology and Hematology, Jikei University Kashiwa Hospital
Department of Hematology, Chiba University Hospital
Department of Internal Medicine, Yuri General Hospital, Yurihonjo
Department of Hematology, Northern Fukushima Medical Center, Date
Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe
Department of Hematology and Oncology, Dokkyo Medical University, Tochigi
Department of Hematology, Chibaken Saiseikai Narashino Hospital
Department of Hematology, Tokyo Medical University Hachioji Medical Center
Transfusion Medicine and Cell Therapy, Mie University Hospital, Tsu
Division of Hematology, National Defense Medical College, Tokorozawa
Department of Hematology, Tokyo Medical and Dental University Hospital;Department of Hematology, Tottori University Hospital, Yonago
Department of Hematology, The Fraternity Memorial Hospital, Tokyo
Clinical Research Promotion and Support Center, Akita University Hospital
Clinical Research Promotion and Support Center, Akita University Hospital
Division of Cancer Immunology, Research Institute / Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Tokyo/Kashiwa
Department of Hematology and Oncology, Japanese Red Cross Narita Hospital;Japanese Red Cross Chiba Blood Center, Funabashi, Japan
Vol. 103 No. 11 (2018): November, 2018 https://doi.org/10.3324/haematol.2018.194894